Please login to the form below

Not currently logged in
Email:
Password:

Celyad appoints Dr David Gilham as R&D vice president

He will resign from the company’s advisory board to fulfill his new role

Celyad Dr David GilhamBelgian biopharmaceutical company Celyad has selected Dr David Gilham to be its new vice president of research and development.

Currently a member of Celyad's immuno-oncology scientific advisory board, Dr Gilham will resign from his post in August to fulfill his new role from 1 September.

Dr Gilham brings extensive experience in the field of CAR-T cells, with his research activity focused on engineering T-cells for cancer therapies and pre-clinical study development. 

Before joining Celyad Dr Gilham was a Reader in the Institute of Cancer Sciences at the University of Manchester, and led the Manchester Cancer Research Centre's clinical and experimental immunotherapy group.

Dr Gilham said: “I am truly excited to be joining Celyad at such an important time in its history.

“Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad's unique portfolio of cell therapy candidates in the clinic.”

16th June 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....